ABU DHABI, 21st May, 2025 (WAM) -- Mohamad Saeed Al Raqbani, General Manager of Dubai Investments Industries and Board Director at Globalpharma, a subsidiary of Dubai Investments, confirmed that the company currently produces over 120 types of pharmaceuticals and exports its products to approximately 18 countries across Africa, the GCC, Eastern Europe and Asia.
In statements to Emirates News Agency (WAM) on the sidelines of the fourth edition of the Make it in the Emirates forum, Al Raqbani said the company aims to expand globally by adopting advanced technologies in the pharmaceutical industry and enhancing its competitiveness in international markets.
He noted that Globalpharma prioritises the development of national talent through strategic partnerships with local and international universities and institutions to train and empower Emirati professionals in this vital and strategic sector.
Al Raqbani highlighted the company’s commitment to the highest global quality standards, having received the Pharmaceutical Quality Award at the Make it in the Emirates Awards, reflecting its ongoing dedication to excellence and innovation.
He stressed that the UAE’s wise leadership’s investment in human capital is bearing fruit, as evidenced by the emergence of pioneering national talent and advanced industrial institutions that compete regionally and globally.
“We are proud to participate in Make it in the Emirates, a key national platform to promote and support local industry,” he said, adding that Globalpharma takes part in the event as a national pharmaceutical manufacturer committed to enhancing the UAE’s pharmaceutical security and delivering high-quality products that meet the highest international standards.
He noted that Globalpharma's production spans a broad range of conventional and advanced medicines, and the company is currently developing biological drugs and herbal products inspired by the UAE’s heritage.
Al Raqbani emphasised that the pharmaceutical industry plays a strategic role in achieving self-sufficiency, with all of Globalpharma's medicines being fully manufactured in the UAE at its facilities in Dubai Investments Park. He added that Make it in the Emirates provides a key opportunity for the national industrial sector to connect with partners, showcase manufacturing capabilities, and explore cooperation and growth prospects both domestically and abroad.
He also revealed that Globalpharma signed four agreements during its participation in the forum with pharmaceutical manufacturers in Canada, Spain, and the Arab Republic of Egypt, as well as with an advanced pharmaceutical research centre in Jordan. These agreements form part of the company’s efforts to expand its regional and international partnerships and strengthen its global presence through advanced pharmaceutical manufacturing that reflects the UAE’s leading position across various fields.